I-MAB Announces Pricing of U.S. Initial Public Offering

Jan  2020

ADSs to Begin Trading on Nasdaq on January 17, 2020

SHANGHAI, China and ROCKVILLE, Md., Jan. 17, 2020  (GLOBE NEWSWIRE)  -- I-Mab (“I- Mab” or the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated  biologics  to   treat   diseases  with   signicant  unmet  medical  needs, particularly   cancers and  autoimmune disorders, today  announced the  pricing  of  its initial public offering  of 7,407,400 American  Depositary Shares (“ADSs”), each ten  (10) ADSs  representing  twenty-three (23)   ordinary   shares  of  the   Company,   par   value US$0.0001 per share,  at US$14.00  per ADS, assuming the underwriters do not exercise their  option  to purchase additional ADSs. The ADSs will begin  trading  on January 17, 2020 on the Nasdaq Global Market under  the symbol  "IMAB".


The Company has  granted the  underwriters an option  to purchase up to an additional 1,111,110 ADSs within 30 days  from  the  date  of the  nal prospectus at US$14.00  per ADS. The total  gross proceeds of the  offering  are  expected to be  approximately  US$ 103,703,600, assuming  the  underwriters  do  not  exercise  their  option   to  purchase additional ADSs,  or  approximately  US$  119,259,140, if  the  underwriters choose  to exercise their option  to purchase additional ADSs in full.


Jefferies  LLC and   China   International  Capital   Corporation  Hong   Kong  Securities Limited are acting  as joint book-running managers  for this offering.  China Renaissance Securities (Hong  Kong)  Limited  and  Huatai  Securities (USA), Inc.  are  acting  as lead managers for this offering.


The Company’s registration statement related to the  offering  has  been  led with, and declared effective by, the  U.S. Securities and  Exchange Commission (the  "SEC"). This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein,  nor shall  there  be any sale  of these securities in any state or jurisdiction in which  such  an  offer,  solicitation, or sale  would  be  unlawful  prior  to registration or qualication under  the securities laws of any such  state or jurisdiction.


Copies  of the prospectus related to the offering  may be obtained from (i) Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520  Madison Avenue,  2nd  Floor,  New York, New York 10022,  by telephone at (877) 821-7388 or by e-mail at Prospectus_Department@Jefferies.com or (ii) China  International Capital  Corporation Hong Kong Securities Limited, Attn: Rita Li, 29th  One International Finance Center, One Harbour  View Street,  Central, Hong Kong, by telephone at (852) 2872-2000 or by e-mail at IB_Genesis2019@cicc.com.cn.


About I-Mab

I-Mab  is  a  dynamic,   global   biotech  company  exclusively   focused  on   developing biologics of novel or highly differentiated in the therapeutic areas of immuno-oncology and  autoimmune diseases. I-Mab's  mission is to bring  transformational  medicines to patients  through innovation. I-Mab's  innovative  pipeline  of more  than  10  clinical  and pre-clinical  stage drug  candidates is  driven  by the  Company's Fast-to-PoC (Proof-of- Concept) and  Fast-to-Market development strategies  through internal  R&D and  global partnerships. The Company is on track  to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven  preclinical and clinical development expertise, and world-class GMP manufacturing capabilities. I- Mab  is  a  private  biopharmaceutical  company with  oces in  China  and  the  United States and has  raised over US$400 million in equity nancing since its establishment in

2016.


Safe Harbor Statement


This   press  release  contains  statements   that    may   constitute  “forward-looking” statements  pursuant to  the  “safe  harbor”  provisions  of  the  U.S.  Private   Securities Litigation  Reform  Act of 1995.  These forward-looking statements can  be identied by terminology such   as “will,”  “expects,”  “anticipates,”  “aims,”  “future,”  “intends,”  “plans,” “believes,”  “estimates,”  “likely to”  and   similar   statements.  Statements that   are  not historical facts,  including  statements about I-Mab’s beliefs,  plans  and expectations, are forward-looking statements. Forward-looking statements involve inherent risks  and uncertainties. Further  information regarding these and other  risks  is included in I-Mab’s lings with the  SEC. All information provided  in this  press release is as of the  date  of this press release, and I-Mab does not undertake any obligation to update any forward- looking statement, except as required under  applicable law.


Investor Relations Contact


I-MAB


Jielun  Zhu, CFO


E-mail: IR@i-mabbiopharma.com


Oce line: 86 21 6057 8000


info@cbridgecap.com
www.cbridgecap.com
© 2020 CBC Group. All Rights Reserved.